Trial Profile
A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary)
- Indications Insulin resistance
- Focus Biomarker; Pharmacodynamics
- Acronyms FEN
- 16 Jul 2012 New trial record
- 15 Jul 2012 Planned end date 1 Apr 2014 added as reported by Netherlands Trial Register record.
- 15 Jul 2012 New source identified and integrated (Netherlands Trial Register, NTR3502).